You are here

  • Home
  • Archive
  • Volume 11, Issue 5
  • Re-sensitization to pembrolizumab following PSMA-CD3 T-cell redirection therapy with JNJ-081 in a patient with mismatch repair-deficient metastatic castration-resistant prostate cancer: a case report

Article info

Article menu

Download PDFPDF

Case report
Re-sensitization to pembrolizumab following PSMA-CD3 T-cell redirection therapy with JNJ-081 in a patient with mismatch repair-deficient metastatic castration-resistant prostate cancer: a case report

Authors

  • Darien E Reed-Perino Division of Oncology, Department of Medicine, University of Washington, Seattle, Washington, USADivision of Human Biology, Fred Hutchinson Cancer Center, Seattle, Washington, USA PubMed articlesGoogle scholar articles
  • Michael Lai Division of Oncology, Department of Medicine, University of Washington, Seattle, Washington, USA PubMed articlesGoogle scholar articles
  • Evan Y Yu Division of Oncology, Department of Medicine, University of Washington, Seattle, Washington, USAClinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA PubMed articlesGoogle scholar articles
  • Michael T Schweizer Division of Oncology, Department of Medicine, University of Washington, Seattle, Washington, USAClinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Michael T Schweizer; schweize{at}uw.edu
View Full Text

Citation

Reed-Perino DE, Lai M, Yu EY, et al
Re-sensitization to pembrolizumab following PSMA-CD3 T-cell redirection therapy with JNJ-081 in a patient with mismatch repair-deficient metastatic castration-resistant prostate cancer: a case report
Journal for ImmunoTherapy of Cancer 2023;11:e006794. doi: 10.1136/jitc-2023-006794

Publication history

  • Accepted May 3, 2023
  • First published May 23, 2023.
Online issue publication 
May 23, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.